SCHEMBL3016039

SCHEMBL3016039

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4ccc(F)cc4)CC3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
TP53 P04637 3/20 0.46
USP2 O75604 1/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
PRKAA2 P54646 1/20 0.43
POLB P06746 1/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.40
OXTR P30559 2/20 0.39
AVPR1A P37288 2/20 0.39
AVPR1B P47901 2/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
KCNH2 Q12809 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021608 0.92 MAPT (0.45) MAPTTP53USP2RECQLHSD17B10
SCHEMBL3014356 0.91 RAB9A (0.41) MAPTTP53RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3017393 0.91 TP53 (0.43) MAPTTP53USP2RECQLHSD17B10
SCHEMBL3002254 0.91 SMN1; SMN2 (0.42) MAPTRECQLPOLBRAB9ASMN1; SMN2
SCHEMBL3006471 0.91 RAB9A (0.41) MAPTRAB9ASMN1; SMN2LMNAOXTR
SCHEMBL3017174 0.91 RAB9A (0.41) MAPTTP53RAB9ASMN1; SMN2ALDH1A1
SCHEMBL3006609 0.90 AVPR1B (0.40) MAPTTP53RAB9ASMN1; SMN2LMNA
SCHEMBL3022765 0.89 GBA1 (0.42) MAPTTP53USP2RECQLHSD17B10
SCHEMBL3010872 0.89 SMN1; SMN2 (0.41) MAPTTP53USP2RECQLHSD17B10
SCHEMBL3018482 0.89 SMN1; SMN2 (0.43) MAPTTP53USP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885TP53 2880/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.